Status:
COMPLETED
The Effect of GCSF in the Treatment of ALS Patients
Lead Sponsor:
Tehran University of Medical Sciences
Conditions:
Amyotrophic Lateral Sclerosis
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
PHASE3
Brief Summary
The aim of this study is to evaluate the effect off Granulocyte Colony Stimulating Factor (GCSF) in the treatment of Amyotrophic Lateral Sclerosis (ALS) patients.
Eligibility Criteria
Inclusion
- age between 18 and 85
- definite or probable ALS according to revised El Escorial criteria
- maximum 2 years from initiation of symptoms to study entry
- mild to moderate disability according to revised ALS functional rating scale (ALSFRS-r)
Exclusion
- familial ALS
- pregnancy or lactation
- myeloproliferative or hematologic disorders
- active immunological disease
- liver or renal or heart disease
- HIV positive
- significant cognitive disorder
- hypersensitivity to GCSF
Key Trial Info
Start Date :
November 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2013
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01825551
Start Date
November 1 2012
End Date
November 1 2013
Last Update
November 13 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Iranian Neurology Research Center of Tehran University of Medical Sciences
Tehran, Tehran Province, Iran